Chimerix signs antiviral deal with Merck; FDA approves interactive insulin pump;

> Chimerix, which uses its lipid-antiviral conjugate technology to improve drug delivery, has signed a deal with Merck ($MRK), giving it access to the HIV antiviral CMX157. Article

> The FDA has approved Roche's ($RHHBY) Accu-Chek Combo interactive insulin pump system. Article

> A hyaluronic acid drug delivery system, delivering 5-fluorouracil over several weeks, could reduce scarring after glaucoma surgery. The study has been shortlisted for a Best Clinical Research Oral Presentation Award at the second SingHealth Duke-NUS Scientific Congress. Article

> NeuroDerm, a transdermal drug delivery developer, is raising $15 million. Article

> Opko Health has signed a research and license agreement for a topically active formulation of the anti-VEGF antibody, ranibizumab, to treat diabetic macular edema. Article

> Airway-targeted PLGA nanoparticles could deliver drugs in obstructive lung disease. Abstract

And Finally… An RNAi drug delivery company secures $1.6M for endosomal escape technology. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.